Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Bergen – page 2

240 clinical trials in Bergen, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Bergen at a glance
240
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

240 trials in Bergen

Open in trial search

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Epstein-Barr virus infection

Recruiting

Safety and Tolerability of Tenofovir Alafenamide Dose Escalation in Healthy Adults for Epstein‑Barr Virus Infection

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tenofovir Alafenamide
  • Sponsor:Helse Bergen HF

Colorectal cancer metastatic

Recruiting

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Systemic lupus erythematosus

Recruiting

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neuroendocrine carcinoma

Recruiting

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Small cell lung cancer

Recruiting

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Stomatitis+1

Recruiting

A study to compare the effectiveness of bupivacaine hydrochloride monohydrate and lidocaine hydrochloride for treating mouth sores in patients with head and neck cancer.

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Lidocaine Hydrochloride

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Hypochondroplasia

Recruiting

Long‑Term Safety and Efficacy of Infigratinib in Children with Hypochondroplasia

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Bergen

What the registry says about research in the country

01 Respiratory Medicine

Innovative clinical trials focusing on pulmonary conditions, including studies of new treatments for idiopathic pulmonary fibrosis and childhood respiratory infections.

  • Idiopathic Pulmonary Fibrosis Treatment
  • Pediatric Respiratory Infections
  • Chronic Wet Cough Studies

Research aims to improve lung function and evaluate new therapeutic approaches for both acute and chronic conditions.

02 Oncology Research

Comprehensive studies in cancer treatment, spanning multiple types including hematological malignancies and solid tumors.

  • Multiple Myeloma Therapies
  • Gastric Cancer Treatment
  • Pediatric Liver Cancer

Advanced trials exploring combination therapies and personalized treatment approaches for various cancer types.

03 Autoimmune Disorders

Investigation of novel treatments for inflammatory conditions, with particular focus on gastrointestinal disorders and chronic fatigue syndrome.

  • Crohn's Disease Management
  • ME/CFS Treatment Studies
  • Innovative Diagnostic Methods

Studies aim to improve disease management and develop new diagnostic techniques.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.